Special-category data at scale
Article 9 health data needs explicit consent or another lawful basis. DPIAs are mandatory. Pseudonymisation rarely fits clinical workflows.
GDPR, NIS2, and cybersecurity for hospitals, pharma, medical devices, and research
One business day reply. Clear next steps and indicative pricing.
From single-site clinics to multinational pharma. The regulatory load changes with patient volume, data sensitivity and product type.
Patient records, breach reporting, AZOP and BfArM liaison.
Clinical trial data, pharmacovigilance, supply-chain integrity.
MDR/IVDR conformity, post-market surveillance, software as MD.
GDPR for health apps, AI Act for diagnostic AI, EHDS interoperability.
Genomic data, research ethics, cross-border data sharing.
IVDR conformity, AI-assisted diagnostics, accreditation regimes.
Eight regimes interlock. We sequence them around your release cadence.
Article 9 lawful basis, DPIA mandatory, breach reporting in 72h, patient rights at scale.
Conformity assessment, CE marking, post-market surveillance, vigilance reporting.
Risk classification, notified body involvement for higher classes, technical documentation.
Risk management, 24h/72h incident reporting, supply-chain security, board accountability.
Patient access to own data, secondary use of health data for research, interoperability obligations.
Annex III medical AI: conformity assessment, technical documentation, human oversight, post-market monitoring.
EU Clinical Trials Information System (CTIS), centralised submission, public transparency.
Stricter consent for cookies, marketing and metadata. Replaces national rules.
Article 9 health data needs explicit consent or another lawful basis. DPIAs are mandatory. Pseudonymisation rarely fits clinical workflows.
Notified bodies are overloaded. Conformity assessment timelines stretched to 18+ months for some classes.
Annex III lists medical AI as high-risk. Conformity, technical file, human oversight, post-market monitoring all required.
Hospitals fall under essential entity scope. Cyber-attacks on healthcare have doubled since 2022.
EU Clinical Trials Regulation centralised submission, but data flows still hit Schrems II issues for US sponsors.
Patient data must be made available for research with safeguards. Anonymisation standards still being defined.
Article 9 mapping, patient rights workflow, DPIA library, breach response, AZOP and BfDI liaison.
Technical documentation, risk management (ISO 14971), notified body submissions, post-market surveillance.
Combined AI Act and MDR conformity, technical file (Annex IV), human oversight, post-market monitoring.
Entity classification, ISMS build, supply-chain assurance, 24h/72h reporting playbook.
CTR Article 81 transparency, CTIS submissions, data flow mapping, transfer impact assessments.
Data interoperability, secondary-use governance, Health Data Access Body engagement.
ICSR data handling, signal management, EudraVigilance integration, GxP-aligned data governance.
Health-app GDPR programme, cross-border telemedicine, patient consent workflows.
Senior DPO with healthcare experience, named to AZOP / BfDI, board reporting, DSAR handling.
Eight questions about your patient base, products and data flows. Get an indicative obligations map across GDPR, MDR, IVDR, NIS2, AI Act and EHDS.
Run obligations mapper~ 4 MINYes. NIS2 Annex I explicitly lists healthcare providers as essential entities. Risk-management measures, 24h early-warning and 72h incident notification apply. Board members carry personal accountability.
If your AI is intended for medical purposes under MDR, it is classified as high-risk under Annex III. You need conformity assessment, technical documentation (Annex IV), human oversight and post-market monitoring on top of MDR obligations.
Yes. We build a combined technical file that satisfies both regimes. The Commission has confirmed alignment between MDR conformity assessment and AI Act conformity, with one notified body sufficient in most cases.
EHDS gives patients access to their own health data and creates a secondary-use regime for research. It applies from March 2026 phased through 2031. We help build the governance and interoperability layers.
Healthcare organisations processing patient data at scale almost always need a DPO under Article 37(1)(c) GDPR. We provide a senior DPO with healthcare-specific experience under retainer.
Trial participants are data subjects with GDPR rights. The Clinical Trials Regulation governs consent and transparency, but GDPR adds the data protection layer. Both apply in parallel.
Health data transfers outside the EEA require GDPR transfer mechanisms (typically SCCs 2021 plus a transfer impact assessment). Most US-EU healthcare partnerships need supplementary measures.
Yes. We coordinate with your chosen notified body, prepare the technical file, manage queries and run dry-run interviews before submission.
GDPR programme for health data, DPIA library and supervisory authority liaison.
Open practice →AI Act conformity for medical AI, combined with MDR conformity assessment.
Open practice →NIS2 scoping, ISMS and supervisory readiness for healthcare essential entities.
Open practice →Typical outcomes: GDPR roadmap, NIS2 priorities, incident response readiness.